Granted Patent
B2
US 9,845,360 · App. 15/256,854 · Granted Dec 19, 2017
Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE
C07K16/2887A61K47/4863A61K47/48561C07K16/00C07K16/18C12N1/20C12N9/2402C12P21/005C12Y302/01096C07K2317/10C07K2317/14C07K2317/41C07K2317/52C07K2317/72C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
Claims (1)
1. A composition comprising at least one Streptococcus pyogenes Endo-S Asp-233 mutant selected from the group consisting of SEQ ID NO:2 (D233Q) and SEQ ID NO: 3 (D233A) and a tris or phosphate buffer.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 25, 2016
From: WANG, LAI-XI; HUANG, WEI
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 040118/0527 →
CONFIRMATORY LICENSE
Recorded Sep 19, 2016
From: UNIVERSITY OF MARYLAND BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039774/0861 →
Continuity (3)
Division
14376248
Provisional Application
61597468
· Feb 10, 2012